MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ROSSI, E. C.
Right arrow Articles by NIMER, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ROSSI, E. C.
Right arrow Articles by NIMER, S.

Molecular Pharmacology, Vol 11, 751-758, Copyright © 1975 by the American Society for Pharmacology and Experimental Therapeutics

The Molecular Components of Nitrofurantoin Critical to Its Inhibitory Effect upon Platelet Aggregation

ENNIO C. ROSSI 1, JOHN J. MIEYAL 1, JOHN M. STRONG 1, GERLINDE LOUIS 1, and STEPHEN NIMER 1

1 Departments of Medicine and Pharmacology and Clinical Pharmacology Unit, Northwestern University School of Medicine, Chicago, Illinois 60611

Nine analogues of nitrofurantoin were studied in order to determine the molecular components critical to its inhibitory effect upon primary ADP-induced platelet aggregation. The structural alterations represented by these analogues indicate that the inhibitory effect of nitrofurantoin is due to the simultaneous presence of the nitro group on the furan ring and the specific arrangement of the diketo groups on the imidazole ring. Molecular orbital calculations predicted the key role of the electron-deficient nitrofurantoin moiety in the inhibitory effect. A specific ADP-nitrofurantoin complex was demonstrated in solution by nuclear magnetic resonance spectroscopy, but the dissociation constant for the complex (approximately 10-1 M) cannot account for the competitive inhibitory effect of nitrofurantoin on platelet aggregation (Ki ap 10-5 M). The over-all data suggest that the nitrofuran and diketoimidazole portions of nitrofurantoin contribute to its inhibitory effect through different mechanisms. These studies also suggest a set of molecular requirements for the synthesis of new inhibitors which could be clinically useful.

Note:
ACKNOWLEDGMENT The authors would like to express their gratitude to Dr. Arthur Atkinson, Jr., for valuable discussions.

Submitted on March 3, 1975







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1975 by the American Society for Pharmacology and Experimental Therapeutics